黑色素瘤刘峰.pptVIP

THANKS T1 T2 Lancet.?2014 Sep 20;384(9948):1109-17 PMID:/pubmed/?term=.+Anti-programmed-death-receptor-1+treatment+with+pembrolizumab+in+ipilimumab-refractory+advanced The?anti-programmed-death-receptor-1?(PD-1) antibody?pembrolizumab?has shown potent antitumour activity at different doses and schedules in patients with melanoma. We compared the efficacy and safety of?pembrolizumab?at doses of 2 mg/kg and 10 mg/kg every 3 weeks in patients with?ipilimumab-refractory?advanced?melanoma. METHODS: In an open-label, international, multicentre expansion cohort of a phase 1 trial, pat